These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17654442)

  • 21. Novel therapies targeting vascular endothelium.
    Tousoulis D; Antoniades C; Koumallos N; Marinou K; Stefanadi E; Latsios G; Stefanadis C
    Endothelium; 2006; 13(6):411-21. PubMed ID: 17169773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes and cardiovascular risk markers.
    Erdmann E
    Curr Med Res Opin; 2005; 21 Suppl 1():S21-8. PubMed ID: 15811196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes.
    Chen LL; Yu F; Zeng TS; Liao YF; Li YM; Ding HC
    Eur J Pharmacol; 2011 Jun; 659(2-3):296-301. PubMed ID: 21453695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin therapy and clinical uses.
    Scarpello JH; Howlett HC
    Diab Vasc Dis Res; 2008 Sep; 5(3):157-67. PubMed ID: 18777488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of insulin resistance on endothelial function, progenitor cells and repair.
    Cubbon RM; Rajwani A; Wheatcroft SB
    Diab Vasc Dis Res; 2007 Jun; 4(2):103-11. PubMed ID: 17654443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelial dysfunction and chronic kidney disease: treatment options.
    Wu-Wong JR
    Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study.
    Tousoulis D; Koniari K; Antoniades C; Miliou A; Noutsou M; Nikolopoulou A; Papageorgiou N; Marinou K; Stefanadi E; Stefanadis C
    Clin Ther; 2010 Sep; 32(10):1720-8. PubMed ID: 21194594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelial dysfunction: potential clinical implications.
    Tousoulis D; Koutsogiannis M; Papageorgiou N; Siasos G; Antoniades C; Tsiamis E; Stefanadis C
    Minerva Med; 2010 Aug; 101(4):271-84. PubMed ID: 21030938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
    Nathanson D; Nyström T
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?
    Schmieder RE
    J Hypertens Suppl; 2006 Apr; 24(2):S31-5. PubMed ID: 16601559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin: a multitasking medication.
    Bailey CJ
    Diab Vasc Dis Res; 2008 Sep; 5(3):156. PubMed ID: 18777487
    [No Abstract]   [Full Text] [Related]  

  • 35. Focus on metformin - a major cardiovascular medication. 'Diabesity - the biggest epidemic in human history'.
    Straughan JL
    Cardiovasc J Afr; 2007; 18(5):331-3. PubMed ID: 17985034
    [No Abstract]   [Full Text] [Related]  

  • 36. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus.
    Guerci B; Böhme P; Kearney-Schwartz A; Zannad F; Drouin P
    Diabetes Metab; 2001 Sep; 27(4 Pt 1):436-47. PubMed ID: 11547217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention.
    Watts GF; Chew KK; Stuckey BG
    Nat Clin Pract Cardiovasc Med; 2007 May; 4(5):263-73. PubMed ID: 17457350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications.
    Tousoulis D; Tsarpalis K; Cokkinos D; Stefanadis C
    Diabetes Obes Metab; 2008 Sep; 10(10):834-42. PubMed ID: 18034844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelial dysfunction in diabetes mellitus.
    Hadi HA; Suwaidi JA
    Vasc Health Risk Manag; 2007; 3(6):853-76. PubMed ID: 18200806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nitric oxide and the endothelium: history and impact on cardiovascular disease.
    Yetik-Anacak G; Catravas JD
    Vascul Pharmacol; 2006 Nov; 45(5):268-76. PubMed ID: 17052961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.